Cargando…

Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study

BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kann, Peter H., Bergmann, Simona, Bidlingmaier, Martin, Dimopoulou, Christina, Pedersen, Birgitte T., Stalla, Günter K., Weber, Matthias M., Meckes-Ferber, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810096/
https://www.ncbi.nlm.nih.gov/pubmed/29433573
http://dx.doi.org/10.1186/s12902-018-0237-3
_version_ 1783299686804750336
author Kann, Peter H.
Bergmann, Simona
Bidlingmaier, Martin
Dimopoulou, Christina
Pedersen, Birgitte T.
Stalla, Günter K.
Weber, Matthias M.
Meckes-Ferber, Stefanie
author_facet Kann, Peter H.
Bergmann, Simona
Bidlingmaier, Martin
Dimopoulou, Christina
Pedersen, Birgitte T.
Stalla, Günter K.
Weber, Matthias M.
Meckes-Ferber, Stefanie
author_sort Kann, Peter H.
collection PubMed
description BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the effect of GH substitution in AGHD. METHODS: The Growth hormone deficiency and Efficacy of Treatment (GET) score (0–100 points) assessed (weighting): HRQoL (40%), disease-related days off work (10%), bone mineral density (20%), waist circumference (10%), low-density lipoprotein cholesterol (10%) and body fat mass (10%). A prospective, non-interventional, multicentre proof-of-concept study investigated whether the score could distinguish between untreated and GH-treated patients with AGHD. A 10-point difference in GET score during a 2-year study period was expected based on pre-existing knowledge of the effect of GH substitution in AGHD. RESULTS: Of 106 patients eligible for analysis, 22 were untreated GHD controls (9 females, mean ± SD age 52 ± 17 years; 13 males, 57 ± 13 years) and 84 were GH-treated (31 females, age 45 ± 13 years, GH dose 0.30 ± 0.16 mg/day; 53 males, age 49 ± 15 years, GH dose 0.25 ± 0.10 mg/day). Follow-up was 706 ± 258 days in females and 653 ± 242 days in males. The GET score differed between the untreated control and treated groups with a least squares mean difference of + 10.01 ± 4.01 (p = 0.0145). CONCLUSIONS: The GET score appeared to be a suitable integrative instrument to summarise the clinical features of GHD and measure the effects of GH substitution in adults. Exercise capacity and muscle strength/body muscle mass could be included in the GET score. TRIAL REGISTRATION: NCT number: NCT00934063. Date of registration: 02 July 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12902-018-0237-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5810096
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58100962018-02-16 Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study Kann, Peter H. Bergmann, Simona Bidlingmaier, Martin Dimopoulou, Christina Pedersen, Birgitte T. Stalla, Günter K. Weber, Matthias M. Meckes-Ferber, Stefanie BMC Endocr Disord Research Article BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the effect of GH substitution in AGHD. METHODS: The Growth hormone deficiency and Efficacy of Treatment (GET) score (0–100 points) assessed (weighting): HRQoL (40%), disease-related days off work (10%), bone mineral density (20%), waist circumference (10%), low-density lipoprotein cholesterol (10%) and body fat mass (10%). A prospective, non-interventional, multicentre proof-of-concept study investigated whether the score could distinguish between untreated and GH-treated patients with AGHD. A 10-point difference in GET score during a 2-year study period was expected based on pre-existing knowledge of the effect of GH substitution in AGHD. RESULTS: Of 106 patients eligible for analysis, 22 were untreated GHD controls (9 females, mean ± SD age 52 ± 17 years; 13 males, 57 ± 13 years) and 84 were GH-treated (31 females, age 45 ± 13 years, GH dose 0.30 ± 0.16 mg/day; 53 males, age 49 ± 15 years, GH dose 0.25 ± 0.10 mg/day). Follow-up was 706 ± 258 days in females and 653 ± 242 days in males. The GET score differed between the untreated control and treated groups with a least squares mean difference of + 10.01 ± 4.01 (p = 0.0145). CONCLUSIONS: The GET score appeared to be a suitable integrative instrument to summarise the clinical features of GHD and measure the effects of GH substitution in adults. Exercise capacity and muscle strength/body muscle mass could be included in the GET score. TRIAL REGISTRATION: NCT number: NCT00934063. Date of registration: 02 July 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12902-018-0237-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-13 /pmc/articles/PMC5810096/ /pubmed/29433573 http://dx.doi.org/10.1186/s12902-018-0237-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kann, Peter H.
Bergmann, Simona
Bidlingmaier, Martin
Dimopoulou, Christina
Pedersen, Birgitte T.
Stalla, Günter K.
Weber, Matthias M.
Meckes-Ferber, Stefanie
Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title_full Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title_fullStr Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title_full_unstemmed Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title_short Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
title_sort design of the growth hormone deficiency and efficacy of treatment (get) score and non-interventional proof of concept study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810096/
https://www.ncbi.nlm.nih.gov/pubmed/29433573
http://dx.doi.org/10.1186/s12902-018-0237-3
work_keys_str_mv AT kannpeterh designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT bergmannsimona designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT bidlingmaiermartin designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT dimopoulouchristina designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT pedersenbirgittet designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT stallagunterk designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT webermatthiasm designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy
AT meckesferberstefanie designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy